Atezolizumab + Bevacizumab [60 mg/mL, 20 mL vial for IV infusion + 25 mg/mL, 4 mL or 16 mL vial for IV infusion] for the treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC)
Cycle 1 | DrugsHTA Council Recommendation (as of 19 January 2026)
As a final recommendation, the HTA Council recommends the government financing of atezolizumab [60 mg/mL, 20 mL vial for intravenous (IV) infusion] + bevacizumab [25 mg/mL, 4 mL or 16 mL vial for IV infusion] as preferred first-line treatment for adults diagnosed with advanced or unresectable hepatocellular carcinoma (HCC)
Relevant Information
- Status: With Final HTA Council Recommendation and SOH Decision
- Topic Assignment: Internal Assessment
- Policy Question: Should atezolizumab [60 mg/mL, 20 mL vial for intravenous (IV) infusion] + bevacizumab [25 mg/mL, 4 mL or 16 mL vial for IV infusion] as preferred first-line treatment for adults diagnosed with advanced or unresectable hepatocellular carcinoma (HCC) be funded by the government?
- Secretary of Health Decision: Approved as of 06 May 2026
Evidence and Relevant Documents